Cytiva acquires CEVEC Pharmaceuticals, strengthening cell line development

By Rachel Arthur

- Last updated on GMT


Related tags Cell lines Cytiva

Cytiva has acquired CEVEC Pharmaceuticals, a German provider of cell line development and viral vector manufacturing technologies.

Headquartered in Köln and founded in 2003, CEVEC Pharmaceuticals provides cell tech for the manufacturing of advanced biotherapeutics from R&D to manufacturing scale: with a portfolio covering various platform technologies for gene therapy vectors, vector vaccines and complex recombinant proteins. This includes its Elevecta tech for AAV manufacturing, CAP Ad tech for RCA-free adenoviral vectors, and CAP Go for production of complex and highly glycosylated recombinant proteins.

Supporting gene and cell therapies

One of the biggest challenges in cell and gene therapy is establishing production processes that can keep up with the increasing demand for volume and consistent quality of viral vectors. With its scalable producer cell lines for vectors based on adeno-associated Virus (AAV) and adenovirus, CEVEC covers two of the most widely used vectors for delivering therapeutic genes to target cells and tissues.

Producer Cell Lines (PCLs), as enabled by CEVEC's Elevecta technology, enable yield, scalability, and robustness in the manufacturing process. With this tech, all components necessary for vector production are stably integrated into the genome of the PCL, offering an alternative to technologies based on transfection or the use of a helper virus.

CEVEC and its 46 scientific experts will become part of therapeutics technology and service provider Cytiva with immediate effect; and its products, services and technologies will continue to be offered under the Elevecta and CAP brands with worldwide availability.

Emmanuel Abate, President, Genomic Medicine at Massachusetts-headquartered Cytiva, said: "Cevec's innovative technology complements Cytiva's offering and brings the promise of improved viral vector manufacturing.

"With Cytiva's global reach and ability to scale, more customers will have access to Cevec's technology and expertise to help accelerate and advance therapeutics for the benefit of patients."

Related news

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Follow us


View more